AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00777023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Trial: NCT02010918
Drug: glucosamine sulfate /chondroitin sulfate - capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
Trial: NCT02010918
Drug: glucosamine sulfate /chondroitin sulfate - sachet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
Trial: NCT02010918
Drug: Cosamin DS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
Trial: NCT02380794
Drug: Danshen Gegen Capsule
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption.
Trial: NCT02380794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03683667
Drug: Azithromycin Oral Product
RxNorm normalized name: azithromycin Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
Trial: NCT03683667
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contain inert excipients only
Trial: NCT03461757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ODT to match rimegepant dose QD
Trial: NCT00270517
Drug: EDP-420 / Duration of Treatment - 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00270517
Drug: Telithromycin / Duration of Treatment - 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04715295
Drug: Doxycycline Tablets
RxNorm normalized name: Doxycycline Tablets
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg daily for 7 days
Trial: NCT03835286
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
Trial: NCT01830335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00932841
Drug: VSL#3 900 billion bacteria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One packet PO daily, x 8 weeks
Trial: NCT00932841
Drug: VSL#3 90 billion bacteria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One packet PO daily, x 8 weeks.
Trial: NCT02601963
Drug: FMX-103 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Trial: NCT02601963
Drug: FMX-103 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Trial: NCT02271503
Drug: CD-LD IR
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
Trial: NCT00836472
Drug: Glucovance® 5 mg/500 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 5 mg/500 mg, single-dose fasting
Trial: NCT00076674
Drug: Intravenous Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01706159
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
Trial: NCT00671320
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
Trial: NCT00671320
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
Trial: NCT03325387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00723164
Drug: Fentanyl and Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
Trial: NCT02190058
Drug: DS-1971a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suspension
Trial: NCT02190058
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching DS-1971a
Trial: NCT02605265
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00575159
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational drug
Trial: NCT00575159
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT00003659
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
Trial: NCT03517085
Drug: steroid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
Trial: NCT00921700
Drug: Ibuprofen + Paracetamol
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
Trial: NCT00921700
Drug: Ibuprofen + Paracetamol + Codeine
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
Trial: NCT00921700
Drug: Paracetamol + Codeine
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
Trial: NCT00921700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of lactose as placebo in gelatine capsules
Trial: NCT01791192
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod
Trial: NCT01791192
Drug: Oral Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Corticosteroid
Trial: NCT00803725
Drug: Mepivacaine without fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg 1.5% mepivacaine injection for spinal anesthesia
Trial: NCT00803725
Drug: Mepivacaine with Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
Trial: NCT03979274
Drug: Reference Eutirox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
Trial: NCT03979274
Drug: Test Eutirox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
Trial: NCT00935558
Drug: aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
Trial: NCT01665144
Drug: BAF312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25, 0.5, 1, and 2 mg film-coated tablets
Trial: NCT01665144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets
Trial: NCT02805101
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodentine is going to be used as the sealing agent for the perforation.
Trial: NCT03824665
Drug: Fentanyl Group
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group F: :(Fentanyl group)1 ml saline containing 20 μg fentanyl used instead of normal saline
Trial: NCT00137254
Drug: Stable Isotopes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of stable isotopes
Trial: NCT04267276
Drug: Part 1: BI 1265162 - intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution
Trial: NCT04267276
Drug: Part 2: BI 1265162 - oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT01160978
Drug: Simvastatin 80mg
RxNorm normalized name: SIMVASTATIN 80MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
Trial: NCT00601627
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00601627
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01670240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01086722
Drug: karolinska cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol
Trial: NCT03824665
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group C (Control group): included patients assigned to receive 1 ml normal saline.
Trial: NCT01488929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00666029
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01818921
Drug: ZGN-440 sterile diluent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZGN-440 sterile diluent/placebo
Trial: NCT01818921
Drug: 1.2 mg ZGN-440 for injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg beloranib
Trial: NCT01818921
Drug: 1.8 mg ZGN-440 for injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg beloranib
Trial: NCT03933865
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be normal saline solution given via intramuscular injection.
Trial: NCT03036748
Drug: Tbl amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
Trial: NCT02215759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01816243
Drug: TTS-Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
Trial: NCT02045849
Drug: GSK2140944 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
Trial: NCT02045849
Drug: GSK2140944 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
Trial: NCT00303459
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching bosentan placebo/b.i.d.
Trial: NCT01088581
Drug: Adjuvant group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (5FU and cisplatin) after resection
Trial: NCT01353742
Drug: Fixed dose combination (Lamivudine and Adefovir dipivoxil)
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg/10mg capsule
Trial: NCT00393874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
Trial: NCT01889979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of a sterile solution was applied in the forearm SC (single dose).
Trial: NCT02139319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01633853
Drug: 1,25(OH)2 Vit D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
Trial: NCT00897260
Drug: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~* Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~* Fludarabine dose adjustment:~  70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion
Trial: NCT00772668
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously per protocol.
Trial: NCT01661621
Drug: Detrusitol 4 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1
Trial: NCT02071407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01610765
Drug: Novel Antiviral Drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
Trial: NCT01610765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
Trial: NCT01380782
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BID oral for 28 day cycle
Trial: NCT00622986
Drug: an extract of Cimicifuga Foetida L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
Trial: NCT00622986
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will be given placebo of 2 tablets each day for 3 months.
Trial: NCT02611154
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
Trial: NCT03676946
Drug: ZKAB001 5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/kg/times bi-week IV administration of ZKAB001
Trial: NCT03676946
Drug: ZKAB001 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg/times bi-week IV administration of ZKAB001
Trial: NCT03676946
Drug: ZKAB001 15mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg/times bi-week IV administration of ZKAB001
Trial: NCT03261167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection will contain sodium chloride (0.9 mg).
Trial: NCT03600363
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebos as a maintenance therapy
Trial: NCT00527267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
Trial: NCT00352599
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00352599
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
Trial: NCT00352599
Drug: placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03352726
Drug: DBV712 IHRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBV712 Solution for Skin Prick Test
Trial: NCT02716610
Drug: INH 139 U
RxNorm normalized name: eflornithine 139 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled human insulin
Trial: NCT02716610
Drug: INH 208 U
RxNorm normalized name: testosterone 0.208 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled human insulin
Trial: NCT01659320
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg twice daily for 8 weeks
Trial: NCT04035317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
Trial: NCT01773408
Drug: RO5503781 SDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
Trial: NCT02251392
Drug: Urea cream based
RxNorm normalized name: urea Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
Trial: NCT04018911
Drug: Hearing Aid with NR_4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
Trial: NCT00917449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo BID for 18 months
Trial: NCT02921971
Drug: SAR156597
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous
Trial: NCT02921971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous
Trial: NCT00077857
Drug: capecitabine (Xeloda®)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.